U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. About FDA
  3. Performance Data
  4. FDA-TRACK: Agency-wide Program Performance
  5. FDA-TRACK: Office of the Chief Medical Officer - Office of Pediatric Therapeutics Dashboard
  1. FDA-TRACK: Agency-wide Program Performance

FDA-TRACK: Office of the Chief Medical Officer - Office of Pediatric Therapeutics Dashboard

 

The Office of Pediatric Therapeutics (OPT) has the primary mission to assure access for children to innovative, safe and effective medical products. Historically, many medical products have not been tested for use in children, leading to an increase in adverse events and the use of ineffective products. Given its legislative mandate, OPT has developed interrelated programs to support FDA efforts to improve information on pediatric therapeutics. Explore the progress OPT is making towards its performance goals below.


Outreach Measures

I. Improve public health by increasing transparency and educational outreach

Return to top


Pediatric Medical Product Safety Measures

I. Provide a public assessment of post-marketing safety information for products studied in the pediatric population in an effort to enhance the understanding of safety issues that arise when products are used in a much broader manner in children than the limited exposures seen in pediatric trials

II. Pediatric Advisory Committee (PAC) Activities

III. Neonatology, Ethics, and Guidance Activities

Return to top


Pediatric Collaboration Measures

I. Enhance scientific content, ethical conduct and safety of pediatric trials in collaboration with international regulatory bodies

II. Enhance scientific content, ethical conduct and safety of international pediatric trials in collaboration with FDA colleagues

Return to top


Download OCMO OPT Dataset


Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time.

 

Sign up to receive FDA-TRACK updates

Get regular FDA email updates delivered on this topic to your inbox.

Back to Top